Back

Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation II Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Mr Jeffrey Trocio

New York (United States of America)

22 More presentations in this session

Presentation thumbnail
Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)
Doctor E. Ridha (London, GB)
Abstract Slides
Presentation thumbnail
Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function
Doctor A. Nissen Bonde (Roskilde, DK)
Presentation thumbnail
In-hospital mortality, length of stay and costs of treating atrial fibrillation or flutter patients admitted for intracranial hemorrhage
Doctor E. Nguyen (Storrs, US)
Abstract Slides
Presentation thumbnail
One-year permeability rate of left atrial appendage closure devices: high incidence of peridevice leak and lack of endothelialization
Doctor G. Laugaudin (Montpellier, FR)
Abstract
Presentation thumbnail
Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation
Professor J. Piccini (Durham, US)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation II

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources